Ivax Corporation has launched its AB-rated gabapentin capsules in 100 mg, 300 mg and 400 mg dosage strengths. Gabapentin is the generic equivalent of Neurontin a drug used to treat epileptic seizures which is marketed by Warner-Lambert, a unit of Pfizer Inc. According to IMS data, for the fourth quarter 2004, US sales of Neurontin and gabapentin in 100, 300 and 400 mg dosage strengths were $337 million.

On February 11, 2005, Ivax entered into a settlement of litigation with the United States Food and Drug Administration and Alpharma Inc. regarding gabapentin. Pursuant to the settlement, Alpharma waived its FDA awarded 180-day exclusivity in favor of Ivax, effective on March 23, 2005 for gabapentin capsules, and April 29, 2005 for gabapentin tablets. As a result, Ivax can market AB rated gabapentin capsules and tablets prior to the expiration of Alpharma's 180-day marketing exclusivity periods.

On August 18, 2004, Ivax launched its non-AB rated gabapentin tablets in 100, 300, and 400 mg dosage strengths. Ivax will continue to market its non-AB rated tablets as well as its AB rated capsules in 100, 300, and 400 mg dosage strengths through its subsidiary, Ivax Pharmaceuticals, Inc.